AlphAIalphai — Financial news for AI agents
investing.comAUG 192 min read$HAE

Haemonetics stock hits 52-week high at 106.64 USD

Haemonetics Corp (HAE) hit a 52-week high of $106.64, up 92.73% over a year. The medical tech firm's stock has surged 72.49% in six months and 14.57% in the past week. Q1 earnings beat estimates, with revenue at $339M. BTIG raised its price target to $96. HAE signed a supply deal with CSL Plasma.

Original reporting
investing.com
Published Aug 19, 2026, 2:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 3:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$HAE
Bullish
high confidence
Mentioned
$HAE
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

Earnings beat and new supply agreement provide fresh positive momentum.

02

Market read

The earnings surprise and contract news could drive short‑term buying pressure.

03

What to watch

No minimum purchase commitments in the CSL Plasma deal could limit revenue upside.

Relevance 7/10Novelty 8/10Timing: after‑hours today

Background

Haemonetics is a medical‑technology company specializing in blood‑management solutions.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Haemonetics reported Q1 earnings of $1.14 EPS beating $1.09 estimate and revenue of $339M beating $328.9M, driving a 14% weekly price rise to a 52‑week high.

Expected impact

Potential further upside of 5‑10% over the next few days.

Evidence & confidence

Strong top‑line, EPS beat, and new supply agreement with CSL Plasma provide fresh positive catalysts.

Market effects

Sector

Positive for the blood‑management and broader medical‑technology sector.

Regional

U.S. healthcare investors may see a modest rally.

Global

Limited to markets tracking U.S. med‑tech stocks.

Counterpoint

What could challenge this read

The stock may be overvalued at its 52‑week high despite the beat.

Key entities

  • Company
    Haemonetics Corp

    Medical‑technology firm reporting Q1 results.

  • Company
    CSL Plasma Inc.

    Partner in a non‑exclusive supply agreement for plasma collection devices.

Read at source← All news

Related articles

AUG 19
$HAEHighAI 8/10

Haemonetics reconnects with CSL in US plasma collection deal

Haemonetics (HAE) announced a new deal with CSL Plasma to supply its NexSys PCS platforms and apheresis kits for U.S. plasma collection centers. The contract, following FDA approval, does not have minimum purchase requirements. HAE shares rose 15% in after-hours trading, reaching $107. Analysts estimate potential revenue of $183M-$223M annually if CSL fully switches back, with a 6%-8% growth rate and 10%-20% pricing premium.

massdevice.com2 min
AUG 18
$HAEMedAI 8/10

Up another 16% TODAY, see why this AI-picked medtech stock is now up +92%

Haemonetics Corporation (NYSE:HAE) rose 15.9% after announcing a supply agreement with CSL Plasma, adding to its 91.88% surge since being identified by InvestingPro's AI models. The company reported Q1 2027 revenue of $339.4M and adjusted EPS of $1.14, raising its full-year revenue growth outlook to 5-8%. InvestingPro's AI-powered stock picker has identified multiple stocks with significant gains, including Haemonetics, which was highlighted for its valuation, profitability, and growth potential

investing.com7 min
AUG 18
$HAEMed

Haemonetics stock surges 16% on CSL Plasma supply deal

Haemonetics (NYSE:HAE) shares rose 16.3% after it announced a non-exclusive U.S. supply agreement with CSL Plasma. Signed Aug. 14, 2026, it allows CSL to use Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables, with no minimum purchase commitments. Haemonetics did not revise fiscal 2027 guidance and plans an update at its Q2 earnings call in Nov. 2026.

investing.com4 min
AUG 18
$HAEHighAI 9/10

Why is Haemonetics stock surging today?

Haemonetics (HAE) shares rose about 6.6% in pre-open after the company filed an 8-K for a non-exclusive supply agreement with CSL Plasma. The deal lets CSL deploy Haemonetics NexSys PCS devices with Persona PLUS and buy related disposables at U.S. centers. Investors also cited Haemonetics’ Aug. 6 Q1 FY2027 results: $339.4M revenue, $1.14 adjusted EPS, and raised FY2027 growth guidance to 5%–8%, plus analyst target increases.

investing.com4 min
AUG 13
$HAEMedAI 8/10

Haemonetics (HAE) Q1 2027 Earnings Call Transcript

Haemonetics (HAE) reported Q1 FY2027 net revenue of $339.4 million, up 5.6% reported and 5.9% organic. Adjusted EPS was $1.14. Management raised FY2027 revenue guidance to 5% to 8% reported and 4% to 7% organic, citing momentum in Plasma and MedSurg, plus higher cash flow and debt paydown.

theglobeandmail.com6 min